CollPlant Biotechnologies Ltd. (CLGN)
0.3203
-0.02
(-6.70%)
USD |
NASDAQ |
Sep 03, 16:00
0.3333
+0.01
(+4.06%)
After-Hours: 19:06
CollPlant Biotechnologies Enterprise Value : 2.974M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | 2.974M |
| September 01, 2026 | 3.396M |
| August 31, 2026 | 3.617M |
| August 28, 2026 | 3.186M |
| August 27, 2026 | 2.200M |
| August 26, 2026 | 2.457M |
| August 25, 2026 | 2.205M |
| August 24, 2026 | 2.360M |
| August 21, 2026 | 2.529M |
| August 20, 2026 | 2.606M |
| August 19, 2026 | 2.663M |
| August 18, 2026 | 2.557M |
| August 17, 2026 | 2.633M |
| August 14, 2026 | 2.777M |
| August 13, 2026 | 2.617M |
| August 12, 2026 | 2.627M |
| August 11, 2026 | 2.277M |
| August 10, 2026 | 2.708M |
| August 07, 2026 | 2.909M |
| August 06, 2026 | 2.792M |
| August 05, 2026 | 2.495M |
| August 04, 2026 | 2.159M |
| August 03, 2026 | 2.609M |
| July 31, 2026 | 1.957M |
| July 30, 2026 | 2.348M |
| Date | Value |
|---|---|
| July 29, 2026 | 2.522M |
| July 28, 2026 | 2.75M |
| July 27, 2026 | 2.622M |
| July 24, 2026 | 2.562M |
| July 23, 2026 | 2.528M |
| July 22, 2026 | 2.638M |
| July 21, 2026 | 2.638M |
| July 20, 2026 | 2.526M |
| July 17, 2026 | 2.854M |
| July 16, 2026 | 2.917M |
| July 15, 2026 | 3.054M |
| July 14, 2026 | 3.286M |
| July 13, 2026 | 3.132M |
| July 10, 2026 | 3.330M |
| July 09, 2026 | 3.217M |
| July 08, 2026 | 3.320M |
| July 07, 2026 | 3.214M |
| July 06, 2026 | 4.192M |
| July 02, 2026 | 2.929M |
| July 01, 2026 | 2.930M |
| June 30, 2026 | 3.054M |
| June 29, 2026 | 3.310M |
| June 26, 2026 | 2.821M |
| June 25, 2026 | 2.924M |
| June 24, 2026 | 2.874M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Anika Therapeutics, Inc. | 275.24M |
| Perspective Therapeutics, Inc. | 120.75M |
| MiMedx Group, Inc. | 544.41M |
| Regentis Biomaterials Ltd. | 52.83M |
| Xylo Technologies Ltd. | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.097M |
| Revenue (Quarterly) | 0.073M |
| Total Expenses (Quarterly) | 3.17M |
| EPS Diluted (Quarterly) | -0.2253 |
| Gross Profit Margin (Quarterly) | -620.5% |
| Profit Margin (Quarterly) | -4.24K% |
| Earnings Yield | -322.3% |
| Normalized Earnings Yield | -322.26 |